News from the CGRP Forum

LIBERTY: full results confirm erenumab’s efficacy in migraine patients unresponsive to previous prophylaxis

Erenumab significantly reduces migraine frequency in patients with episodic migraine who have not responded to other preventive treatments, according to the LIBERTY study. At the end of 12 weeks, patients taking erenumab had nearly three-fold higher odds of having their migraine days reduced by at least 50% (weeks 9-12: 30.3% with erenumab, 13.7% with placebo, p=0.002, odds ratio 2.73).

Read the full report here »